According to Teva, the company’s DuoResp Spiromax budesonide/formoterol fumarate inhalation powder has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP). The company has applied to market the product in Europe for the treatment of asthma and COPD.
Teva President of Global R&D and Chief Scientific Officer Michael Hayden said, “We have planned for strong growth in Respiratory. The Spiromax inhaler is an important addition to our Respiratory portfolio and supports our strategy to become a leading presence in Respiratory with a robust and differentiated pipeline, projected to be a multi-billion dollar franchise by the end of the decade.”
The company says that it plans to submit applications for DuoResp Spiromax “in a number of countries worldwide.”
Read the Teva press release.
